For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...
Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...
Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...
That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...
Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...
On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB), an estimated $2.93 million trade based on quarterly average pricing. Nuvation Bio is ...
Q32 Bio on Monday sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results